






Ophthotech Corp.  
 Investor Relations Department  
 Five Vaughn Drive  
 Suite 106  
 Princeton, NJ 08540  
 United States

[Visit IR website](#)   
[Sign-up for email alerts](#) 

**NASDAQ: OPHT** <sup>1</sup>

Last Trade:	2.51
Trade Time:	4:00 PM ET Oct 16, 2017
Change:	-0.12  (4.563%)
Day Range	2.48 - 2.65
52-Week Range	2.24 - 40.34
Volume	451,684
Market Cap. (\$M)	90.209
Shares Out (M)	35.940


<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

### Company Profile

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.

... [\(more\)](#)

### Stock Performance



### Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

### Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

- Feb 28, 2017*  
[Annual Report \(10-K\)](#)
- Apr 24, 2017*  
[Definitive Proxy Statement](#)
- Aug 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*  
[Quarterly Report \(10-Q\)](#)